Association of CDKN2B-AS1 rs1333049 with Brain Diseases: A Case-control Study and a Meta-analysis

IF 2.4 4区 医学 Q3 NEUROSCIENCES Clinical Psychopharmacology and Neuroscience Pub Date : 2017-02-01 DOI:10.9758/cpn.2017.15.1.53
Jikuang Zhao, Xizheng Wu, S. Nie, Xiang Gao, Jie Sun, Keqin Li, Tiefeng Zhang, Yi Huang
{"title":"Association of CDKN2B-AS1 rs1333049 with Brain Diseases: A Case-control Study and a Meta-analysis","authors":"Jikuang Zhao, Xizheng Wu, S. Nie, Xiang Gao, Jie Sun, Keqin Li, Tiefeng Zhang, Yi Huang","doi":"10.9758/cpn.2017.15.1.53","DOIUrl":null,"url":null,"abstract":"Objective CDKN2B-AS1 polymorphisms were shown to associate with the risk of stroke in European. The goal of this study was to evaluate the contribution of CDKN2B-AS1 rs1333049 to the risk of hemorrhagic stroke (HS) and brain tumor (BT) in Han Chinese. Methods A total of 142 HSs, 115 BTs, and 494 controls were included in the current association study. The genotyping test was performed using the melting temperature shift method. Results We failed to validate the association of CDKN2B-AS1 rs1333049 with the risk of brain disease. Significantly higher levels of low-density lipoprotein cholesterol (LDL-C) (p=0.027), high-density lipoprotein cholesterol (HDL-C) (p<0.001) and total cholesterol (TC) (p<0.001) were found in HSs in the genotype GG/GC carriers, but not the genotype CC carriers (p>0.05). The meta-analysis of 10 studies among 133,993 individuals concluded that rs1333049 of CDKN2B-AS1 gene was likely to increase a 16% incidence rate of cerebrovascular disease (CD) among various populations (odds ratio 1.16, 95% confidence interval 1.08–1.25; p<0.0001, random-effect method). Conclusion Our case-control study identified rs1333049 genotypes showed different association with the concentration of the LDL-C, HDL-C and TC in the HS patients. Meta-analysis supported the association between rs1333049 and CD risk in various populations, although we were unable to observe association between rs1333049 and the risk of HSs in Han Chinese.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"15 1","pages":"53 - 58"},"PeriodicalIF":2.4000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychopharmacology and Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.9758/cpn.2017.15.1.53","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 12

Abstract

Objective CDKN2B-AS1 polymorphisms were shown to associate with the risk of stroke in European. The goal of this study was to evaluate the contribution of CDKN2B-AS1 rs1333049 to the risk of hemorrhagic stroke (HS) and brain tumor (BT) in Han Chinese. Methods A total of 142 HSs, 115 BTs, and 494 controls were included in the current association study. The genotyping test was performed using the melting temperature shift method. Results We failed to validate the association of CDKN2B-AS1 rs1333049 with the risk of brain disease. Significantly higher levels of low-density lipoprotein cholesterol (LDL-C) (p=0.027), high-density lipoprotein cholesterol (HDL-C) (p<0.001) and total cholesterol (TC) (p<0.001) were found in HSs in the genotype GG/GC carriers, but not the genotype CC carriers (p>0.05). The meta-analysis of 10 studies among 133,993 individuals concluded that rs1333049 of CDKN2B-AS1 gene was likely to increase a 16% incidence rate of cerebrovascular disease (CD) among various populations (odds ratio 1.16, 95% confidence interval 1.08–1.25; p<0.0001, random-effect method). Conclusion Our case-control study identified rs1333049 genotypes showed different association with the concentration of the LDL-C, HDL-C and TC in the HS patients. Meta-analysis supported the association between rs1333049 and CD risk in various populations, although we were unable to observe association between rs1333049 and the risk of HSs in Han Chinese.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CDKN2B-AS1 rs1333049与脑疾病的相关性:病例对照研究和荟萃分析
目的CDKN2B-AS1多态性与欧洲人脑卒中的风险有关。本研究的目的是评估CDKN2B-AS1 rs1333049对汉族人出血性中风(HS)和脑肿瘤(BT)风险的贡献。方法本研究共纳入142例HS、115例BT和494例对照组。基因分型试验采用熔融温度偏移法进行。结果我们未能验证CDKN2B-AS1 rs1333049与脑疾病风险的相关性。低密度脂蛋白胆固醇(LDL-C)水平显著升高(p=0.027),高密度脂蛋白胆固醇(HDL-C)(p0.05)。对133993名个体的10项研究进行的荟萃分析得出结论,CDKN2B-AS1基因的rs1333049可能在不同人群中增加16%的脑血管病(CD)发病率(比值比1.16,95%置信区间1.08-1.25;p<0.0001,随机效应法)。结论我们的病例对照研究发现rs1333049基因型和HS患者的LDL-C、HDL-C和TC浓度有不同的相关性。荟萃分析支持rs1333049与不同人群CD风险之间的相关性,尽管我们无法观察到rs1333040与汉族人HSs风险之间的关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Psychopharmacology and Neuroscience
Clinical Psychopharmacology and Neuroscience NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY
CiteScore
4.70
自引率
12.50%
发文量
81
期刊介绍: Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.
期刊最新文献
Clinical Reasoning in the Use of Long-acting Aripiprazole in Psychosis in Bilateral Nephrectomy on Hemodialysis. Enhancing the Understanding of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies in Chronic Migraine Prevention. Psychometric Properties of Korean Version of Nonsuicidal Self-injury Inventory: Validation Study of Deliberate Self-harm Inventory. Psychosomatics: Communication of the Central Nervous System through Connection to Tissues, Organs, and Cells. Remembering Chae Won Kim, Pioneer of Psychopharmacology in Korea.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1